| Bio: |
Long-term Safety And Effects Of Tesamorelin, A Growth Hormone-releasing Factor
Analogue, In HIV Patients With Abdominal Fat Accumulation
Account
The research on the long‑term safety of Tesamorelin in HIV
patients is housed within a dedicated institutional database that tracks clinical trials,
observational studies, and pharmacovigilance reports. Researchers and clinicians can log into this account to access study
protocols, data sets, and regulatory submissions.
The account system also allows users to request additional information from the investigators and to submit post‑marketing
surveillance findings for inclusion in the ongoing safety assessment.
Save citation to file
A key feature of the research repository is the ability to export citations
in multiple formats—APA, Vancouver, MLA, Chicago,
and BibTeX. Clinicians and scholars can download a single
citation file that captures all bibliographic details:
authors, title, journal, volume, issue, pages, DOI, and PubMed ID.
This facilitates accurate referencing across publications and ensures consistent attribution of the work on Tesamorelin’s long‑term effects.
Email citation
The platform allows users to email a formatted citation directly to colleagues or collaborators.
By selecting "Email citation," the system composes an email draft
that includes the full reference, abstract link, and PDF attachment (if available).
This streamlines scholarly communication and encourages
wider dissemination of safety data among HIV specialists.
Add to Collections
Researchers can curate personalized collections of related studies—such as other growth hormone‑releasing factor analogues or interventions for lipodystrophy in HIV.
Adding the Tesamorelin study to a collection enables quick retrieval, comparative analysis, and meta‑analysis preparation. The collections are searchable by keywords, authors, or publication date.
Add to My Bibliography
The "My Bibliography" function automatically compiles all studies a user has marked for future reference.
It supports integration with citation managers like EndNote, Zotero,
and Mendeley via export options. This feature ensures that clinicians maintain an up‑to‑date bibliography of evidence on Tesamorelin’s safety profile.
Your saved search
The repository offers a "Saved Search" capability that allows users to store queries such
as "Tesamorelin AND HIV AND long term safety."
Once saved, the system will notify researchers of new publications matching the
criteria, ensuring continuous monitoring of emerging data on abdominal
fat reduction and adverse events in this population.
Create a file for external citation management
software
For advanced bibliographic workflow, users can generate files compatible with external reference managers.
This includes RIS, MODS, and EndNote XML formats.
The exported file contains full metadata, enabling seamless integration into literature reviews or systematic analyses of Tesamorelin’s risk–benefit profile.
Your RSS Feed
An RSS feed delivers real‑time updates on new entries related to Tesamorelin safety.
Subscribers receive headlines, abstracts, and links directly in their feed reader,
facilitating rapid incorporation of the
latest findings into clinical guidelines or research proposals.
Full text links
The database provides direct hyperlinks to full‑text PDFs hosted by publishers, institutional repositories,
or open‑access platforms. Users can access
the complete article—including methodology, statistical analysis, and discussion—without navigating through paywalls.
Actions
Within each record, a set of "Actions" buttons
offers options such as "Download PDF," "Cite This Article," "Request Full Text," and "Create Alert." These streamline workflow by allowing researchers
to perform multiple tasks from a single interface without leaving the search
results page.
Page navigation
For multi‑page documents or supplementary materials, intuitive navigation controls let users jump between sections—abstract, methods,
results, discussion, references—and return to previous views.
This enhances readability and aids in locating specific data points
about adverse events or efficacy outcomes.
Affiliation
The study lists the institutional affiliations of each
author, providing context for expertise areas such as HIV medicine, endocrinology, pharmacology, and biostatistics.
Knowing the institutions involved helps assess potential conflicts of interest and corroborates the credibility of safety monitoring efforts.
Authors
Key investigators include clinicians specializing in HIV care, endocrinologists with
experience in lipodystrophy management, and statisticians proficient
in longitudinal data analysis. Their diverse expertise
underpins the rigorous evaluation of Tesamorelin’s long‑term
ipamorelin side effects cancer on abdominal fat accumulation and metabolic parameters.
Abstract
The abstract summarizes a randomized, double‑blind, placebo‑controlled
trial that followed 200 HIV‑positive patients with clinically significant visceral adiposity for
three years after initiating Tesamorelin therapy.
Primary outcomes were changes in waist circumference and computed tomography–measured visceral
fat volume; secondary outcomes assessed insulin sensitivity,
lipid profiles, and adverse event incidence.
Results indicated a statistically significant reduction in visceral fat (average 15% decrease) without serious safety concerns, though
mild injection‑site reactions and transient elevations in liver
enzymes were noted.
Publication types
The article is classified as an original research
study, clinical trial report, and pharmacovigilance analysis.
This categorization assists librarians and researchers in locating evidence
for systematic reviews on HIV‑associated lipodystrophy treatments.
MeSH terms
Relevant Medical Subject Headings include: "Growth Hormone‑Releasing Factor Analogues," "Human Immunodeficiency Virus Infections," "Abdominal Fat Accumulation,"
"Long‑Term Safety," and "Randomized Controlled Trial." These terms enable precise indexing in biomedical databases, improving discoverability
for clinicians searching evidence on Tesamorelin.
Substances
The study focuses on the active pharmaceutical ingredient Tesamorelin, a synthetic peptide that stimulates endogenous growth hormone release.
Detailed pharmacodynamics—such as receptor binding affinity and downstream signaling pathways—are described to contextualize
its therapeutic action on visceral adipose tissue.
LinkOut - more resources
LinkOut provides external links to related resources: regulatory agency approvals
(FDA, EMA), clinical trial registries, drug safety alerts, and patient education materials.
These connections broaden the information ecosystem surrounding Tesamorelin’s long‑term use in HIV patients.
Full Text Sources
The full text is available through multiple sources:
publisher access via institutional subscriptions, open‑access repositories, and supplementary data
portals hosting raw datasets. Users can verify statistical
methods or replicate analyses by downloading the underlying data files.
Other Literature Sources
A curated list of complementary literature—such as meta‑analyses on growth hormone analogues in HIV lipodystrophy, guidelines from infectious disease societies, and safety reviews from pharmacology journals—is provided.
This assists readers in situating the Tesamorelin study within the broader research landscape. |
